{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:44:51Z","timestamp":1789501491284,"version":"build-2803163510"},"reference-count":171,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>During the past two decades there has been a major shift in the choice of agents to treat multiple myeloma, whether newly diagnosed or in the relapsed\/refractory stage. The introduction of new drug classes, such as proteasome inhibitors, immunomodulators, and anti-CD38 and anti-SLAMF7 monoclonal antibodies, coupled with autologous stem cell transplantation, has approximately doubled the disease\u2019s five-year survival rate. However, this positive news is tempered by the realization that these measures are not curative and patients eventually relapse and\/or become resistant to the drug\u2019s effects. Thus, there is a need to discover newer myeloma-driving molecular markers and develop innovative drugs designed to precisely regulate the actions of such putative targets. B cell maturation antigen (BCMA), which is found almost exclusively on the surfaces of malignant plasma cells to the exclusion of other cell types, including their normal counterparts, has emerged as a specific target of interest in this regard. Immunotherapeutic agents have been at the forefront of research designed to block BCMA activity. These agents encompass monoclonal antibodies, such as the drug conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified by AMG 420; and chimeric antigen receptor (CAR) T-cell therapeutics that include idecabtagene vicleucel (bb2121) and JNJ-68284528.<\/jats:p>","DOI":"10.3390\/ijms21155192","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:14:06Z","timestamp":1595499246000},"page":"5192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and\/or Refractory Multiple Myeloma"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-1926","authenticated-orcid":false,"given":"Hanley N.","family":"Abramson","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: Multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_5","unstructured":"(2020). SEER Cancer Statistics Review (CSR) 1975\u20132017: Myeloma."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-981-32-9717-3_3","article-title":"The TNF-TNFR family of co-signal molecules","volume":"1189","author":"So","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1002\/jcp.28445","article-title":"The role of BAFF and APRIL in rheumatoid arthritis","volume":"234","author":"Shabgah","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL\u2014A proliferation inducing ligand\u2014In autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3892\/ol.2017.6528","article-title":"Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1038\/bcj.2015.3","article-title":"B-cell activating factor in the pathophysiology of multiple myeloma: A target for therapy?","volume":"5","author":"Hengeveld","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom\u2019s macroglobulinemia: A phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2019.37.15_suppl.8012","article-title":"Phase 1 study of safety and tolerability of BION-1301 in patients with relapsed or refractory multiple myeloma","volume":"37","author":"Bensinger","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V81.2.454.454","article-title":"Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes","volume":"81","author":"Kozlow","year":"1993","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4049\/jimmunol.149.2.735","article-title":"A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily","volume":"149","author":"Zhou","year":"1992","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"Raman","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/cbf.3169","article-title":"Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways","volume":"34","author":"Shen","year":"2016","journal-title":"Cell Biochem. Funct."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18632\/oncotarget.109","article-title":"A critical role for the NFkB pathway in multiple myeloma","volume":"1","author":"Demchenko","year":"2010","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood-2006-05-024372","article-title":"STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90 alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival","volume":"109","author":"Chatterjee","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/sj.leu.2403486","article-title":"PI3-K\/AKT\/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells","volume":"18","author":"Lentzsch","year":"2004","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","article-title":"Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells","volume":"104","author":"Chatterjee","year":"2004","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"Gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"Gamma-secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","article-title":"Notch signaling: An emerging therapeutic target for cancer treatment","volume":"369","author":"Yuan","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1074\/mcp.R112.026005","article-title":"Glycoproteomic analysis of antibodies","volume":"12","author":"Zauner","year":"2013","journal-title":"Mol. Cell. Proteom."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14712598.6.11.1161","article-title":"Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies","volume":"6","author":"Satoh","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10616-007-9103-2","article-title":"Non-fucosylated therapeutic antibodies: The next generation of therapeutic antibodies","volume":"55","author":"Mori","year":"2007","journal-title":"Cytotechnology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V130.Suppl_1.741.741","article-title":"Deep and durable responses in patients (pts) with relapsed\/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against B-cell maturation antigen (BCMA): Preliminary results from part 2 of study BMA117159","volume":"130","author":"Trudel","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2019-129879","article-title":"Dreamm-5: Platform trial evaluating belantamab mafodotin (a BCMA-directed immuno-conjugate) in combination with novel agents in relapsed or refractory multiple myeloma (RRMM)","volume":"134","author":"Richardson","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"TPS3107","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3107","article-title":"ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"TPS3113","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3113","article-title":"INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors","volume":"35","author":"Angevin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2018.07.003","article-title":"Stimulating T cells against cancer with agonist immunostimulatory monoclonal antibodies","volume":"342","author":"Han","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","article-title":"DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Nooka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"key":"ref_48","first-page":"3153","article-title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1158\/1538-7445.AM2018-3833","article-title":"SEA-BCMA: A highly active enhanced antibody for multiple myeloma","volume":"78","author":"Anderson","year":"2018","journal-title":"Cancer Res."},{"key":"ref_50","unstructured":"Nikitorowicz-Buniak, J. (2020, June 11). FDA Safety Concerns Halt ACTR087 B Cell Non-Hodgkin Lymphoma Clinical Trial. Available online: https:\/\/lymphomahub.com\/medical-information\/fda-safety-concerns-halt-actr087-b-cell-non-hodgkin-lymphoma-clinical-trial."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, Y., Park, J., Liu, X., Hu, Y., Wang, T., McFarland, K., and Betenbaugh, M.J. (2019). Design and production of bispecific antibodies. Antibodies (Basel, Switzerland), 8.","DOI":"10.3390\/antib8030043"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: Overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: Hitting two targets with one sophisticated arrow","volume":"14","author":"Fateh","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ctrv.2018.04.002","article-title":"Bispecific antibodies in haematological malignancies","volume":"65","author":"Viardot","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2050","article-title":"Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells","volume":"12","author":"Thiery","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"40098","DOI":"10.1038\/srep40098","article-title":"Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence","volume":"7","author":"Mazor","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/bjc.1998.518","article-title":"The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: Relevance for immunotherapy of carcinomas","volume":"78","author":"Velders","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","article-title":"Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.clml.2019.09.082","article-title":"AMG 701, a half-life extended anti-BCMA BiTE\u00ae, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment","volume":"19","author":"Cho","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood-2019-126818","article-title":"Safety and preliminary clinical activity of REGN5458, an anti-BCMA x anti-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1182\/blood.V128.22.5668.5668","article-title":"Exploratory pharmacokinetic\/pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys","volume":"128","author":"Girgis","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"17253","DOI":"10.1038\/s41598-018-35489-y","article-title":"Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance","volume":"8","author":"Suzuki","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","article-title":"A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma","volume":"132","author":"Lesokhin","year":"2018","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)\u2013CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"128","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","article-title":"Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies","volume":"11","author":"Trinklein","year":"2019","journal-title":"mAbs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood-2019-123220","article-title":"A multicenter, phase 1, open-label, dose-escalation and expansion study of TNB-383B, a bispecific antibody targeting BCMA in subjects with relapsed or refractory multiple myeloma","volume":"134","author":"Buelow","year":"2019","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and nonclinical characterization of HPN217: A tri-Specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: First global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: Blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Strohl, W.R., and Naso, M. (2019). Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies (Basel, Switzerland), 8.","DOI":"10.3390\/antib8030041"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Godel","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Tey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_96","first-page":"18","article-title":"Biology drives the discovery of bispecific antibodies as innovative therapeutics","volume":"3","author":"Nie","year":"2020","journal-title":"Antib. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"V808","DOI":"10.1093\/annonc\/mdz269.038","article-title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","volume":"30","author":"Li","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1182\/blood.V128.22.4513.4513","article-title":"Trispecific antibodies for selective CD16A-directed NK-cell engagement in multiple myeloma","volume":"128","author":"Gantke","year":"2016","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1158\/1538-7445.AM2019-4972","article-title":"Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma","volume":"79","author":"Draghi","year":"2019","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Guzman","year":"2019","journal-title":"Blood"},{"key":"ref_102","first-page":"1927","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"35","author":"Ross","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Roex, G., Feys, T., Beguin, Y., Kerre, T., Poire, X., Lewalle, P., Vandenberghe, P., Bron, D., and Anguille, S. (2020). Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: An update of the pivotal clinical trial data. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020194"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance\u2014The story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11899-016-0336-z","article-title":"Chimeric antigen receptor T cells for B cell neoplasms: Choose the right CAR for you","volume":"11","author":"Ruella","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Radic, M. (2012). Armed and accurate: Engineering cytotoxic T cells for eradication of leukemia. BMC Biotechnol., 12.","DOI":"10.1186\/1472-6750-12-6"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.3747\/co.27.5283","article-title":"Chimeric antigen receptor T cell therapy comes to clinical practice","volume":"27","author":"Wall","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-020-0706-6","article-title":"Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"21","author":"Badar","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","article-title":"Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: A review","volume":"6","author":"Locke","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: Chimeric antigen receptor T cells targeting CD19","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Hamieh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.2005.16.457","article-title":"Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions","volume":"16","author":"Hughes","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCP63TOCFNAMDMS","article-title":"The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: A new statistical model","volume":"137","author":"Cannizzo","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jcp.48.6.548","article-title":"CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance","volume":"48","author":"Zandecki","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"103964","DOI":"10.1016\/j.cellimm.2019.103964","article-title":"The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"345","author":"Feinberg","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s12185-020-02827-8","article-title":"Chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"111","author":"Hosen","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1631\/jzus.B1900351","article-title":"Current advances in chimeric antigen receptor T-cell therapy for refractory\/relapsed multiple myeloma","volume":"21","author":"Huang","year":"2020","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_132","unstructured":"(2020, June 12). Press Release (Brisol Myers Squibb, 6 December 2019). Available online: https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-and-bluebird-bio-announce-positive-top-li."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","article-title":"Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-cell maturation antigen, in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: A phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2018-99-111419","article-title":"Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)","volume":"132","author":"Gregory","year":"2018","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: Final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","article-title":"Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.clml.2019.09.283","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for control of multiple myeloma","volume":"19","author":"Lin","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): Initial safety and efficacy from a phase I study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2018-99-117964","article-title":"Tandom autologous transplantation and combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for high risk MM: Initial safety and efficacy report from a clinical pilot study","volume":"132","author":"Shi","year":"2018","journal-title":"Blood"},{"key":"ref_149","first-page":"506","article-title":"Combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for RRMM: Initial safety and efficacy report from a clinical pilot study","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: Beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2019-129088","article-title":"T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1038\/s41467-019-13088-3","article-title":"Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality","volume":"10","author":"Sachdeva","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtn.2017.10.005","article-title":"Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy","volume":"9","author":"Gautron","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_154","unstructured":"Li, C., Zhou, X., Wang, J., Hu, G., Yang, Y., Meng, L., Hong, Z., Chen, L., and Zhou, J. (2019, January 12\u201315). Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T cell therapy in relapsed\/refractory multiple myeloma. Proceedings of the 17th International Myeloma Workshop, Boston, MA, USA. OAB-033."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1097-2765(00)80146-X","article-title":"DNA recognition and cleavage by the LAGLIDADG homing endonuclease I-CreI","volume":"2","author":"Jurica","year":"1998","journal-title":"Mol. Cell"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T Cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_158","unstructured":"(2020, June 12). Press Release (Bristol Myers Squibb, 31 March 2020). Available online: https:\/\/news.bms.com\/press-release\/celltherapy\/bristol-myers-squibb-and-bluebird-bio-announce-submission-biologics-licens."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"ref_160","first-page":"563","article-title":"Engineering a targeted delivery platform using Centyrins","volume":"29","author":"Goldberg","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat. Med."},{"key":"ref_162","first-page":"3473","article-title":"CAR T-cell therapy: Is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"ref_164","unstructured":"(2020, June 18). Press Release (CARsgen Therapeutics Co. Ltd. 28 October 2019). Available online: https:\/\/www.prnewswire.com\/news-releases\/carsgen-announces-investigational-car-t-therapy-ct053-granted-rmat-designation-by-the-us-fda-for-rr-multiple-myeloma-300945966.html."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2019-128468","article-title":"Efficacy and safety of fully human BCMA targeting CAR T cell therapy in relapsed\/refractory multiple myeloma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"ref_166","first-page":"504","article-title":"T cells expressing anti-B-cell maturation antigen (BCMA) chimeric antigen receptors with antigen recognition domains made up of only single human heavy chain variable domains specifically recognize BCMA and eradicate tumors in mice","volume":"130","author":"Lam","year":"2017","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1016\/j.clml.2019.09.035","article-title":"Off-the-shelf AlloCAR T (TM) cells targeting BCMA for the treatment of multiple myeloma","volume":"19","author":"Sommer","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"8972","DOI":"10.1038\/s41598-018-27264-w","article-title":"A versatile safeguard for chimeric antigen receptor T-cell immunotherapies","volume":"8","author":"Valton","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1038\/s41598-018-28599-0","article-title":"Understanding the indirect DNA read-out specificity of I-CreI meganuclease","volume":"8","author":"Prieto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_170","first-page":"97","article-title":"Generation of two new immunotherapeutic products with genetically modified NK cells. Comparison of clinically relevant CARS in multiple myeloma","volume":"104","author":"Encinas","year":"2019","journal-title":"Haematologica"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1016\/j.clml.2019.09.036","article-title":"Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma","volume":"19","author":"Martin","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/15\/5192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:45Z","timestamp":1760176245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/15\/5192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":171,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["ijms21155192"],"URL":"https:\/\/doi.org\/10.3390\/ijms21155192","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202007.0016.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}